journal article·2024-02Open access

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles

Soraia Fernandes, Marco Cassani, Francesca Cavalieri, Giancarlo Forte, Frank Caruso

Advanced Science· Volume 11· Issue 8

Abstract

Abstract The application of lipid‐based nanoparticles for COVID‐19 vaccines and transthyretin‐mediated amyloidosis treatment have highlighted their potential for translation to cancer therapy. However, their use in delivering drugs to solid tumors is limited by ineffective targeting, heterogeneous organ distribution, systemic inflammatory responses, and insufficient drug accumulation at the tumor. Instead, the use of lipid‐based nanoparticles to remotely activate immune system responses is an emerging effective strategy. Despite this approach showing potential for treating hematological cancers, its application to treat solid tumors is hampered by the selection of eligible targets, tumor heterogeneity, and ineffective penetration of activated T cells within the tumor. Notwithstanding, the use of lipid‐based nanoparticles for immunotherapy is projected to revolutionize cancer therapy, with the ultimate goal of rendering cancer a chronic disease. However, the translational success is likely to depend on the use of predictive tumor models in preclinical studies, simulating the complexity of the tumor microenvironment (e.g., the fibrotic extracellular matrix that impairs therapeutic outcomes) and stimulating tumor progression. This review compiles recent advances in the field of antitumor lipid‐based nanoparticles and highlights emerging therapeutic approaches (e.g., mechanotherapy) to modulate tumor stiffness and improve T cell infiltration, and the use of organoids to better guide therapeutic outcomes.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · CAR-T cell therapy research · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Translational Medicine (CTM) International Clinical Research Centre (ICRC) St. Anne Hospital Brno 656 91 Czech Republic

Department of Chemical Engineering The University of Melbourne Parkville Victoria 3010 Australia

School of Science RMIT University Melbourne Victoria 3000 Australia

Dipartimento di Scienze e Tecnologie Chimiche Universita di Roma “Tor Vergata” Via della Ricerca Scientifica 1 Rome 00133 Italy

School of Cardiovascular and Metabolic Medicine & Sciences King's College London London SE5 9NU UK

Funding

Horizon 2020 · National Health and Medical Research Council · Ministerstvo Zdravotnictví Ceské Republiky

References (100+)

Show source-provided references
1. 10.1002/anbr.20210010910.1002/anbr.202100109 ↗
2. 10.1002/adma.20230326110.1002/adma.202303261 ↗
3. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
4. 10.1038/mtna.2014.6110.1038/mtna.2014.61 ↗
5. 10.1021/acs.nanolett.1c0197310.1021/acs.nanolett.1c01973 ↗
6. 10.1002/adfm.20210139110.1002/adfm.202101391 ↗
7. 10.1038/s41467-022-31993-y10.1038/s41467-022-31993-y ↗
8. 10.1021/acsami.3c0150110.1021/acsami.3c01501 ↗
9. 10.1021/acs.accounts.8b0049310.1021/acs.accounts.8b00493 ↗
10. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
11. 10.1038/s41392-022-01007-w10.1038/s41392-022-01007-w ↗
12. 10.1038/s41467-021-27493-010.1038/s41467-021-27493-0 ↗
13. 10.1038/s41551-021-00698-w10.1038/s41551-021-00698-w ↗
14. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
15. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
16. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
17. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
18. 10.1002/advs.20230192910.1002/advs.202301929 ↗
19. 10.1038/s41578-022-00529-710.1038/s41578-022-00529-7 ↗
20. 10.1038/s41417-019-0141-710.1038/s41417-019-0141-7 ↗
21. 10.1016/j.jconrel.2006.04.01410.1016/j.jconrel.2006.04.014 ↗
22. 10.1038/nm.435610.1038/nm.4356 ↗
23. 10.1038/s41587-022-01294-210.1038/s41587-022-01294-2 ↗
24. 10.1126/sciadv.abj543510.1126/sciadv.abj5435 ↗
25. 10.1007/s40265-018-0983-610.1007/s40265-018-0983-6 ↗
26. 10.1016/j.addr.2023.11486110.1016/j.addr.2023.114861 ↗
27. Gabizon A. · Cancer Res · 1983 · 43 · 4730
28. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
29. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
30. 10.2174/092986732766620062515113410.2174/0929867327666200625151134 ↗
31. 10.1080/14737140.2016.119247110.1080/14737140.2016.1192471 ↗
32. 10.1080/10428194.2019.166097010.1080/10428194.2019.1660970 ↗
33. 10.1021/acsnano.3c0608510.1021/acsnano.3c06085 ↗
34. 10.1002/advs.20210344410.1002/advs.202103444 ↗
35. 10.1039/D0SC06557A10.1039/D0SC06557A ↗
36. 10.1016/j.jconrel.2016.04.02810.1016/j.jconrel.2016.04.028 ↗
37. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
38. 10.1080/17425247.2017.126234610.1080/17425247.2017.1262346 ↗
39. 10.1038/nrd427810.1038/nrd4278 ↗
40. 10.1038/s41392-020-0207-x10.1038/s41392-020-0207-x ↗
41. 10.1038/mtna.2015.2310.1038/mtna.2015.23 ↗
42. 10.1007/s40265-020-01269-010.1007/s40265-020-01269-0 ↗
43. 10.1634/theoncologist.2018-083810.1634/theoncologist.2018-0838 ↗
44. 10.1038/s43586-022-00104-y10.1038/s43586-022-00104-y ↗
45. 10.1089/hum.2020.13710.1089/hum.2020.137 ↗
46. 10.1016/j.omtn.2022.02.02010.1016/j.omtn.2022.02.020 ↗
47. 10.1016/j.ymthe.2022.02.01610.1016/j.ymthe.2022.02.016 ↗
48. ClinicalTrials.gov https://www.clinicaltrials.gov/ accessed: June 2023.
49. 10.1016/j.cell.2023.02.03110.1016/j.cell.2023.02.031 ↗
50. 10.1186/s13045-021-01056-810.1186/s13045-021-01056-8 ↗
51. 10.1038/s41416-018-0325-110.1038/s41416-018-0325-1 ↗
52. 10.1038/s41571-020-0347-510.1038/s41571-020-0347-5 ↗
53. 10.1038/s41571-022-00600-w10.1038/s41571-022-00600-w ↗
54. 10.1038/s12276-018-0191-110.1038/s12276-018-0191-1 ↗
55. 10.1038/bjc.2017.43410.1038/bjc.2017.434 ↗
56. 10.1186/s40364-021-00294-910.1186/s40364-021-00294-9 ↗
57. 10.1038/s41408-021-00459-710.1038/s41408-021-00459-7 ↗
58. 10.1007/s40005-022-00569-910.1007/s40005-022-00569-9 ↗
59. 10.1126/science.abm059410.1126/science.abm0594 ↗
60. 10.1038/s41467-020-19486-210.1038/s41467-020-19486-2 ↗
61. 10.1016/j.ymthe.2022.05.01810.1016/j.ymthe.2022.05.018 ↗
62. 10.1126/science.aay596710.1126/science.aay5967 ↗
63. 10.1186/s12943-021-01348-010.1186/s12943-021-01348-0 ↗
64. 10.1038/s41392-017-0002-510.1038/s41392-017-0002-5 ↗
65. 10.1136/jitc-2022-00640110.1136/jitc-2022-006401 ↗
66. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
67. 10.1038/s41467-020-18794-x10.1038/s41467-020-18794-x ↗
68. 10.1038/s41568-018-0006-710.1038/s41568-018-0006-7 ↗
69. 10.1038/s41392-021-00641-010.1038/s41392-021-00641-0 ↗
70. 10.1038/s41568-019-0238-110.1038/s41568-019-0238-1 ↗
71. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
72. 10.1016/j.matbio.2023.11.00110.1016/j.matbio.2023.11.001 ↗
73. 10.1016/j.tcb.2018.12.00110.1016/j.tcb.2018.12.001 ↗
74. 10.3389/fmolb.2019.0016010.3389/fmolb.2019.00160 ↗
75. 10.1186/s12989-017-0199-z10.1186/s12989-017-0199-z ↗
76. 10.4161/onci.2023910.4161/onci.20239 ↗
77. 10.3389/fphar.2022.86869510.3389/fphar.2022.868695 ↗
78. 10.1038/nrc109310.1038/nrc1093 ↗
79. 10.1016/j.canlet.2020.09.02610.1016/j.canlet.2020.09.026 ↗
80. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
81. 10.1002/adma.20210635010.1002/adma.202106350 ↗
82. 10.1038/s41467-023-37328-910.1038/s41467-023-37328-9 ↗
83. 10.1158/2159-8290.CD-13-098510.1158/2159-8290.CD-13-0985 ↗
84. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
85. 10.1038/nrc324510.1038/nrc3245 ↗
86. 10.1158/0008-5472.CAN-11-321810.1158/0008-5472.CAN-11-3218 ↗
87. Marit M. M. · J. Immunother. Cancer · 2023 · 1110.1136/jitc-2022-006401 ↗
88. 10.1038/s41467-021-25282-310.1038/s41467-021-25282-3 ↗
89. 10.1016/j.matbio.2019.02.00310.1016/j.matbio.2019.02.003 ↗
90. 10.1016/j.ceb.2010.08.01510.1016/j.ceb.2010.08.015 ↗
91. 10.1172/JCI4581710.1172/JCI45817 ↗
92. 10.1038/s41467-022-27960-210.1038/s41467-022-27960-2 ↗
93. 10.1016/j.eclinm.2022.10153510.1016/j.eclinm.2022.101535 ↗
94. 10.1158/1078-0432.CCR-20-047310.1158/1078-0432.CCR-20-0473 ↗
95. 10.1016/j.medidd.2020.10002310.1016/j.medidd.2020.100023 ↗
96. 10.18632/oncotarget.1045310.18632/oncotarget.10453 ↗
97. 10.1016/j.it.2020.04.00410.1016/j.it.2020.04.004 ↗
98. 10.1007/s00262-020-02625-510.1007/s00262-020-02625-5 ↗
99. 10.1016/j.jconrel.2022.03.02110.1016/j.jconrel.2022.03.021 ↗
100. 10.1158/1078-0432.CCR-20-047210.1158/1078-0432.CCR-20-0472 ↗